Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. / Smith, Steven R; O'Neil, Patrick M; Astrup, Arne; Finer, Nicholas; Sanchez-Kam, Matilde; Fraher, Kyle; Fain, Randi; Shanahan, William R.

I: Obesity, Bind 22, Nr. 10, 2014, s. 2137-2146.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Smith, SR, O'Neil, PM, Astrup, A, Finer, N, Sanchez-Kam, M, Fraher, K, Fain, R & Shanahan, WR 2014, 'Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes', Obesity, bind 22, nr. 10, s. 2137-2146. https://doi.org/10.1002/oby.20841

APA

Smith, S. R., O'Neil, P. M., Astrup, A., Finer, N., Sanchez-Kam, M., Fraher, K., ... Shanahan, W. R. (2014). Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. Obesity, 22(10), 2137-2146. https://doi.org/10.1002/oby.20841

Vancouver

Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K o.a. Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. Obesity. 2014;22(10):2137-2146. https://doi.org/10.1002/oby.20841

Author

Smith, Steven R ; O'Neil, Patrick M ; Astrup, Arne ; Finer, Nicholas ; Sanchez-Kam, Matilde ; Fraher, Kyle ; Fain, Randi ; Shanahan, William R. / Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. I: Obesity. 2014 ; Bind 22, Nr. 10. s. 2137-2146.

Bibtex

@article{3a7775fbef1a407cbb4c44b7da3a863d,
title = "Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes",
abstract = "OBJECTIVE: To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5{\%} weight loss at Week (W) 52 in patients with and without type 2 diabetes on lorcaserin or placebo.METHODS: Post hoc area under the curve for receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo with lifestyle modification+lorcaserin. A total of 6897 patients (18-65 years; BMI, 30-45 or 27-29.9 kg/m(2) with ≥1 comorbidity) were randomized to placebo or lorcaserin 10 mg bid. Changes (baseline to W52) in cardiometabolic parameters were assessed.RESULTS: Response (≥5{\%} weight loss from baseline) at W12 was a strong predictor of W52 response. Lorcaserin patients with a W12 response achieved mean W52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving ≥5{\%} and ≥10{\%} weight loss at W52 were 85.5{\%} and 49.8{\%} (without diabetes), and 70.5{\%} and 35.9{\%} (with diabetes). Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent-to-treat (MITT) population, consistent with greater weight loss.CONCLUSIONS: ≥5{\%} weight loss by W12 predicts robust response to lorcaserin at 1 year.",
author = "Smith, {Steven R} and O'Neil, {Patrick M} and Arne Astrup and Nicholas Finer and Matilde Sanchez-Kam and Kyle Fraher and Randi Fain and Shanahan, {William R}",
note = "CURIS 2014 NEXS 223",
year = "2014",
doi = "10.1002/oby.20841",
language = "English",
volume = "22",
pages = "2137--2146",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes

AU - Smith, Steven R

AU - O'Neil, Patrick M

AU - Astrup, Arne

AU - Finer, Nicholas

AU - Sanchez-Kam, Matilde

AU - Fraher, Kyle

AU - Fain, Randi

AU - Shanahan, William R

N1 - CURIS 2014 NEXS 223

PY - 2014

Y1 - 2014

N2 - OBJECTIVE: To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5% weight loss at Week (W) 52 in patients with and without type 2 diabetes on lorcaserin or placebo.METHODS: Post hoc area under the curve for receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo with lifestyle modification+lorcaserin. A total of 6897 patients (18-65 years; BMI, 30-45 or 27-29.9 kg/m(2) with ≥1 comorbidity) were randomized to placebo or lorcaserin 10 mg bid. Changes (baseline to W52) in cardiometabolic parameters were assessed.RESULTS: Response (≥5% weight loss from baseline) at W12 was a strong predictor of W52 response. Lorcaserin patients with a W12 response achieved mean W52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving ≥5% and ≥10% weight loss at W52 were 85.5% and 49.8% (without diabetes), and 70.5% and 35.9% (with diabetes). Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent-to-treat (MITT) population, consistent with greater weight loss.CONCLUSIONS: ≥5% weight loss by W12 predicts robust response to lorcaserin at 1 year.

AB - OBJECTIVE: To identify an early treatment milestone that optimizes sensitivity and specificity for predicting ≥5% weight loss at Week (W) 52 in patients with and without type 2 diabetes on lorcaserin or placebo.METHODS: Post hoc area under the curve for receiver operating characteristic analyses of data from three phase 3 trials comparing lifestyle modification+placebo with lifestyle modification+lorcaserin. A total of 6897 patients (18-65 years; BMI, 30-45 or 27-29.9 kg/m(2) with ≥1 comorbidity) were randomized to placebo or lorcaserin 10 mg bid. Changes (baseline to W52) in cardiometabolic parameters were assessed.RESULTS: Response (≥5% weight loss from baseline) at W12 was a strong predictor of W52 response. Lorcaserin patients with a W12 response achieved mean W52 weight losses of 10.6 kg (without diabetes) and 9.3 kg (with diabetes). Proportions achieving ≥5% and ≥10% weight loss at W52 were 85.5% and 49.8% (without diabetes), and 70.5% and 35.9% (with diabetes). Lorcaserin patients who did not achieve a W12 response lost 3.2 kg (without diabetes) and 2.8 kg (with diabetes) at W52. Responders had greater improvements in cardiometabolic risk factors than the modified intent-to-treat (MITT) population, consistent with greater weight loss.CONCLUSIONS: ≥5% weight loss by W12 predicts robust response to lorcaserin at 1 year.

U2 - 10.1002/oby.20841

DO - 10.1002/oby.20841

M3 - Journal article

C2 - 25044799

VL - 22

SP - 2137

EP - 2146

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 10

ER -

ID: 120071466